Recent blog posts
Comprehensive understanding of Proton Pump Inhibitors
Comprehensive understanding of Proton Pump Inhibitors
4 September 2023
Proton pumps are enzymes found in the stomach lining that play a crucial role in the production of gastric acid.
Read →
Unveiling the Veil of JAK Inhibitors
Unveiling the Veil of JAK Inhibitors
4 September 2023
JAK inhibitors can inhibit JAK kinases, block the JAK-STAT signaling pathway, and have great therapeutic potential for a variety of diseases including tumors, immune & inflammation···
Read →
MAO Inhibitors -the Redemption of Depression
MAO Inhibitors -the Redemption of Depression
4 September 2023
Monoamine Oxidase(MAO) is a naturally existing oxidase in the human body, located on the outer membrane of mitochondria.
Read →
ACE inhibitor -Overview of its R&D Progress | Competitive Landscape | Key Drug
ACE inhibitor -Overview of its R&D Progress | Competitive Landscape | Key Drug
4 September 2023
ACE, or angiotensin-converting enzyme, plays a crucial role in the human body by regulating blood pressure and fluid balance.
Read →
SGLT2 Inhibitors - The Cross-Domain Superstar of Antidiabetic Drugs
SGLT2 Inhibitors - The Cross-Domain Superstar of Antidiabetic Drugs
2 September 2023
SGLT2 inhibitors use a unique insulin-independent mechanism to lower blood glucose levels, not only effectively and safely reducing glucose, but also providing significant cardio-renal protection.
Read →
PCSK9 inhibitors: A new promising lipid-lowering therapy
PCSK9 inhibitors: A new promising lipid-lowering therapy
1 September 2023
PCSK9 is a serine protease synthesized by the liver, which can bind to and degrade the low-density lipoprotein receptor (LDL-R), reducing LDL-R's clearance of low-density lipoprotein cholesterol (LDL-C) in the serum.
Read →
How does AstraZeneca's PARP inhibitor differentiate?
Valuable Targets
10 min read
How does AstraZeneca's PARP inhibitor differentiate?
28 August 2023
PARP inhibitors had once brought about a "decade breakthrough" for ovarian cancer, and in search for new areas of business growth, AZ is primarily seeking the approval for the use of olaparib in metastatic prostate cancer.
Read →
Sales fall short of expectations, how can KRAS G12C be differentiated in R&D?
Valuable Targets
10 min read
Sales fall short of expectations, how can KRAS G12C be differentiated in R&D?
25 August 2023
With KRAS, a previously considered untouchable target, being cracked open, the KRAS G12C inhibitors of Amgen and Mirati are now on the market. The question is, how can we further optimize treatment outcomes for patients?
Read →
AstraZeneca leads the development of small molecule RXFP1 agonists
Valuable Targets
10 min read
AstraZeneca leads the development of small molecule RXFP1 agonists
21 August 2023
Relaxin Family Peptide Receptor 1 (RXFP1) is the receptor of relaxin-2, and relaxin-2 is an important regulator of reproduction and cardiovascular physiology.
Read →
Progress in the Research and Development of METTL3 Drug Targets
Progress in the Research and Development of METTL3 Drug Targets
21 August 2023
METTL3 is an RNA methyltransferase that catalyzes the methylation of RNA at N6-adenosine, making it a key player in this process.
Read →
Progress in the Research and Development of p53 Y220C Drug Targets
Progress in the Research and Development of p53 Y220C Drug Targets
21 August 2023
The Y220C target mutation is a common oncogenic missense mutation, with a slightly lower mutation frequency compared to R249S and G245S located on the DNA binding surface.
Read →
Progress in the Research and Development of PI3Kα Drug Targets
Progress in the Research and Development of PI3Kα Drug Targets
16 August 2023
PI3Kα is a crucial lipid kinase and one of the most frequently mutated kinases in cancer. It consists of a heterodimer composed of the catalytic subunit p110α and the regulatory subunit p85α.
Read →